Immunological characterization of peripheral blood samples inpatients with pulmonary cachexia

MU Klinikum, Medizinische Klinik und Poliklinik V0 个研究点目标入组 80 人开始时间: 2024年7月9日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•underlying disease currently assumed to be stable, no emergency treatment with hospitalization >24 h in the last 4 weeks
•- no antibiotic or hematopoietic (G-CSF) treatment in the last 4 weeks
•- patient is able to read and answer questionnaires
•- patient is able to perform lung function and diffusion measurement
•- Patient able to perform a hand force measurement

•- patient age <18 years, patient not capable of giving informed consent
•- unclear primary diagnosis (e.g.: suspected COPD, inclusion in the study can be reconsidered if the diagnosis is confirmed)
•-severe known comorbidity associated with the development of cachexia, e.g. second malignancy, HIV infection (exception: concomitant COPD in NSCLC)
•- Lack of weight gain during childhood development with a long-term low BMI <20 kg/m2
•- known serious eating disorder, e.g. anorexia nervosa
•- currently desired weight loss, e.g. as part of a diet
•- anamnestic or documented Covid-19 infection within the last month
•- pregnancy
•- known critical anemia (Hb <8 g/dl)
•- known high-grade cardiac arrhythmia
•- known or documented allergy to nonivamide/nicobixil, as well as electrode patches
•- after implantation of automatic, electronic devices, e.g. pacemakers
•- after heart transplantation, lung transplantation

发起方

MU Klinikum, Medizinische Klinik und Poliklinik V